These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 25788408)

  • 1. New drug combination may shorten tuberculosis treatment, study says.
    Mayor S
    BMJ; 2015 Mar; 350():h1518. PubMed ID: 25788408
    [No Abstract]   [Full Text] [Related]  

  • 2. New effective antituberculosis regimens.
    Sotgiu G; Migliori GB
    Lancet; 2015 May; 385(9979):1703-1704. PubMed ID: 25795077
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.
    Wolfson LJ; Gibbert J; Wirth D; Diel R
    Eur Respir J; 2015 Dec; 46(6):1826-9. PubMed ID: 26493796
    [No Abstract]   [Full Text] [Related]  

  • 5. Advances in the treatment of tuberculosis.
    Zhang Y
    Clin Pharmacol Ther; 2007 Nov; 82(5):595-600. PubMed ID: 17898708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No evidence that pyrazinamide resistance is acquired after fluoroquinolone resistance.
    Cobelens F; Gebhard A; van den Hof S
    Int J Tuberc Lung Dis; 2016 Feb; 20(2):282. PubMed ID: 26792486
    [No Abstract]   [Full Text] [Related]  

  • 7. High Incidence of New-Onset Joint Pain in Patients on Fluoroquinolones as Antituberculous Treatment.
    Mandovra NP; Lele TT; Vaidya PJ; Chavhan VB; Leuppi-Taegtmeyer AB; Leuppi JD; Chhajed PN
    Respiration; 2020; 99(2):125-131. PubMed ID: 31935716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In reply.
    Takiff H; Alame-Emane AK; Pierre-Audigier C; Gicquel B
    Int J Tuberc Lung Dis; 2016 Feb; 20(2):282-3. PubMed ID: 26792487
    [No Abstract]   [Full Text] [Related]  

  • 9. Delamanid (Deltyba°) and multidrug-resistant pulmonary tuberculosis.
    Prescrire Int; 2017 Apr; 26(181):89-92. PubMed ID: 30730656
    [No Abstract]   [Full Text] [Related]  

  • 10. [Respiratory fluoroquinolones and pulmonary tuberculosis treatment when the main drugs are ineffective].
    Lazareva NB; Khaĭmenova TIu; Khaĭmenov AIa
    Antibiot Khimioter; 2008; 53(5-6):14-20. PubMed ID: 19069177
    [No Abstract]   [Full Text] [Related]  

  • 11. Fluoroquinolone and pyrazinamide resistance in multidrug-resistant tuberculosis.
    Pierre-Audigier C; Surcouf C; Cadet-Daniel V; Namouchi A; Heng S; Murray A; Guillard B; Gicquel B
    Int J Tuberc Lung Dis; 2012 Feb; 16(2):221-3, i-ii. PubMed ID: 22236923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PA-824 , moxifloxacin and pyrazinamide combination therapy for tuberculosis.
    Dawson R; Diacon A
    Expert Opin Investig Drugs; 2013 Jul; 22(7):927-32. PubMed ID: 23687915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How are we creating fluoroquinolone-resistant tuberculosis?
    Bernardo J; Yew WW
    Am J Respir Crit Care Med; 2009 Aug; 180(4):288-9. PubMed ID: 19661251
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug resistance pattern in multidrug resistance pulmonary tuberculosis patients.
    Rao NA; Irfan M; Soomro MM; Mehfooz Z
    J Coll Physicians Surg Pak; 2010 Apr; 20(4):262-5. PubMed ID: 20392404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen.
    Dutta NK; Alsultan A; Gniadek TJ; Belchis DA; Pinn ML; Mdluli KE; Nuermberger EL; Peloquin CA; Karakousis PC
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3910-6. PubMed ID: 23733473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoroquinolones for the treatment of pulmonary tuberculosis.
    Moadebi S; Harder CK; Fitzgerald MJ; Elwood KR; Marra F
    Drugs; 2007; 67(14):2077-99. PubMed ID: 17883288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pulmonary tuberculosis caused by Mycobacterium bovis with primary resistance to Isoniazide and pyrazinamide].
    Blanco Ramos JR; Rosel Rioja L; Dopereiro Gómez R; Oteo Revuelta JA
    An Med Interna; 1997 Aug; 14(8):433-4. PubMed ID: 9376493
    [No Abstract]   [Full Text] [Related]  

  • 18. [Sparfloxacin in combined therapy for pulmonary tuberculosis].
    Sokolova GB; Khaĭmenova TIu; Lazareva IaV; Khaĭmenov AIa
    Antibiot Khimioter; 2008; 53(5-6):21-7. PubMed ID: 19069178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
    Diacon AH; Dawson R; von Groote-Bidlingmaier F; Symons G; Venter A; Donald PR; van Niekerk C; Everitt D; Hutchings J; Burger DA; Schall R; Mendel CM
    Am J Respir Crit Care Med; 2015 Apr; 191(8):943-53. PubMed ID: 25622149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Floracide, a Russian 3rd generation fluoroquinolone in complex therapy of tuberculosis].
    Sokolova GB; Kirtaeva OV; Lazareva IaV; Tsybanev AA
    Antibiot Khimioter; 2008; 53(5-6):28-31. PubMed ID: 19069179
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.